Postinfarction therapy with beta blockers: who should be treated?
D000319:Adrenergic beta-Antagonists / Q000009:adverse effects / Q000627:therapeutic use*; D000526:Alprenolol / Q000494:pharmacology / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D006321:Heart / Q000503:physiopathology; D006801:Humans; D008790:Metoprolol / Q000494:pharmacology / Q000627:therapeutic use; D009203:Myocardial Infarction / Q000188:drug therapy*; D011433:Propranolol / Q000494:pharmacology / Q000627:therapeutic use; D011897:Random Allocation; D013999:Timolol / Q000494:pharmacology / Q000627:therapeutic use
D000319:Adrenergic beta-Antagonists; D013999:Timolol; D000526:Alprenolol; D011433:Propranolol; D008790:Metoprolol